Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Campaign To Boost Generics Gets Thumbs Up From European Industry Body

Executive Summary

The French health ministry is hoping a new campaign aimed at increasing the use of generics and dispelling any remaining doubts about their quality among the public will bring cost savings.

You may also be interested in...



France 2017: More Price Cuts, Rebates, Generics and Biosimilars, And A New Innovation Fund

The French pharmaceutical industry has reacted angrily to some of the provisions in the 2017 social security financing bill, arguing that the measures are inappropriate and that the government is taking a purely financial approach to addressing the costs of healthcare products, rather than taking wider public health considerations into account.

French unveil plan to save €350m through greater use of generics

The French government has unveiled plans to boost the prescribing and dispensing of generic medicines, with a view to making an additional €350m in savings over the next three years. Most of the measures are aimed at healthcare professionals and the public, although the authorities have called on pharmaceutical firms to help by printing the INN more prominently on product packs.

EU Falsified Medicines Directive ‘Not Working’ In Northern Ireland

Industry representatives told a House of Lords committee about continuing Brexit-related problems such as the extra work involved in checking compliance with the EU Falsified Medicines Directive and the drawbacks of a proposed “dual regulatory regime.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS119292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel